Central hypoadrenalism

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages 4027-4036

  Crowley, R K ^a   Argese, N ^a   Tomlinson, J W ^a   Stewart, P M ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; CYTOCHROME P450 3A4; DEXAMETHASONE; ESTROGEN; FLUTICASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; PRASTERONE; PREDNISOLONE; STEROID;

ADRENAL CORTEX ADENOMA; ADRENAL DISEASE; ADRENAL FUNCTION; ADRENAL SUPPRESSION; ASTHMA; BIOEQUIVALENCE; BRONCHIECTASIS; CENTRAL HYPOADRENALISM; CORTICOTROPIN DEFICIENCY; CUSHING DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOCRINE SURGERY; HUMAN; HYPERCORTISOLISM; HYPOPHYSIS DISEASE; HYPOPHYSIS TUMOR; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN TOLERANCE TEST; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; ADRENAL INSUFFICIENCY; COMPLICATION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMIC DISEASES; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PATHOPHYSIOLOGY; PITUITARY DISEASES;

ADRENAL INSUFFICIENCY; HUMANS; HYPOTHALAMIC DISEASES; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY DISEASES; PITUITARY-ADRENAL SYSTEM;

EID: 84909993072     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2476     Document Type: Review

References (116)

1. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361: 1881-1893.
2. Diez-Perez A, Hooven FH, Adachi JD, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49: 493-498.
3. Clark PM, Neylon I, Raggatt PR, Sheppard MC, Stewart PM. Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clin Endocrinol (Oxf). 1998;49: 287-292.
4. Sherlock M, Reulen RC, Alonso AA, et al. ACTHdeficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94: 4216-4223.
5. Hannon MJ, Crowley RK, Behan LA, et al. Acute glucocorticoid deficiency and diabetes insipidus are common after acute traumatic brain injury and predict mortality. J Clin Endocrinol Metab. 2013; 98: 3229-3237.
6. Zueger T, Kirchner P, Herren C, et al. Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab. 2012;97: E1938-E1942.
7. Chrousos GP, Kino T, Charmandari E. Evaluation of the hypothalamic- pituitary-adrenal axis function in childhood and adolescence. Neuroimmunomodulation. 2009;16: 272-283.
8. Raffin-Sanson ML, de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. Eur J Endocrinol. 2003;149: 79-90.
9. Cooray SN, Clark AJ. Melanocortin receptors and their accessory proteins. Mol Cell Endocrinol. 2010;331: 215-221.
10. Cooper MS, Stewart PM. Diagnosis and treatment of ACTH deficiency. Rev Endocr Metab Disord. 2005;6: 47-54.
11. Grossman AB. Clinical review: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab. 2010;95: 4855-4863.
12. Kino T, Charmandari E, Chrousos GP. Glucocorticoid receptor: implications for rheumatic diseases. Clin Exp Rheumatol. 2011; 29: S32-S41.
13. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991;72: 39-45.
14. Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab. 1993;76: 1505-1510.
15. Kenny FM, Gancayco GP, Heald FP, Hung W. Cortisol production rate in adolescent males in different stages of sexual maturation. J Clin Endocrinol Metab. 1966;26: 1232-1236.
16. Briassoulis G, Damjanovic S, Xekouki P, Lefebvre H, Stratakis CA. The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic- pituitary-adrenal axis function; implications for pituitary and adrenal tumors. Endocr Pract. 2011;17: 941-948.
17. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19: 155-157.
18. Lamolet B, Pulichino AM, Lamonerie T, et al. A pituitary cellrestricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001;104: 849-859.
19. Drouin J, Bilodeau S, Vallette S. Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet. 2007;72: 175-182.
20. Quentien MH, Delemer B, Papadimitriou DT, et al. Deficit in anterior pituitary function and variable immune deficiency (DAVID) in children presenting with adrenocorticotropin deficiency and severe infections. J Clin Endocrinol Metab. 2012;97: E121-E128.
21. Samuels ME, Gallo-Payet N, Pinard S, et al. Bioinactive ACTH causing glucocorticoid deficiency. J Clin Endocrinol Metab. 2013; 98: 736-742.
22. Vallette-Kasic S, Barlier A, Teinturier C, et al. PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. J Clin Endocrinol Metab. 2001;86: 4529-4535.
23. Rajab A, Kelberman D, de Castro SC, et al. Novel mutations in LHX3are associated with hypopituitarism and sensorineural hearing loss. Hum Mol Genet. 2008;17: 2150-2159.
24. Tajima T, Hattori T, Nakajima T, Okuhara K, Tsubaki J, Fujieda K. A novel missense mutation (P366T) of the LHX4 gene causes severe combined pituitary hormone deficiency with pituitary hypoplasia, ectopic posterior lobe and a poorly developed sella turcica. Endocr J. 2007;54: 637-641.
25. Carvalho LR, Woods KS, Mendonca BB, et al. A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction. J Clin Invest. 2003;112: 1192-1201.
26. Diaczok D, Romero C, Zunich J, Marshall I, Radovick S. A novel dominant negative mutation of OTX2 associated with combined pituitary hormone deficiency. J Clin Endocrinol Metab. 2008;93: 4351-4359.
27. Glezer A, Bronstein MD. Pituitary autoimmune disease: nuances in clinical presentation. Endocrine. 2012;42: 74-79.
28. Bellastella G, Rotondi M, Pane E, et al. Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up. J Clin Endocrinol Metab. 2010; 95: 3750-3757.
29. Crowley RK, Hamnvik OP, O'Sullivan EP, et al. Morbidity and mortality in patients with craniopharyngioma after surgery. Clin Endocrinol (Oxf). 2010;73: 516-521.
30. Agha A, Thompson CJ. Anterior pituitary dysfunction following traumatic brain injury (TBI). Clin Endocrinol (Oxf). 2006;64: 481-488.
31. Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab. 2005;90: 6355-6360.
32. Ingle DJ, Kendall EC. Atrophy of the adrenal cortex of the rat produced by the administration of large amounts of cortin. Science. 1937;86: 245.
33. Quirke V. Making British cortisone: Glaxo and the development of corticosteroids in Britain in the 1950s-1960s. Stud Hist Philos Biol Biomed Sci. 2005;36: 645-674.
34. Boland EW, Headley NE. Results of long-continued cortisone administration in rheumatoid arthritis. Calif Med. 1951;74: 416-423.
35. Santiago AH, Ratzan S. Acute adrenal crisis in an asthmatic child treated with inhaled fluticasone proprionate. Int J Pediatr Endocrinol. 2010;2010.
36. Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24: 714-720.
37. Mader R, Lavi I, Luboshitzky R. Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone. Arthritis Rheum. 2005;52: 924-928.
38. van Velsen SG, DeRoos MP, Haeck IM, Sparidans RW, Bruijnzeel-Koomen CA. The potency of clobetasol propionate: serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis. J Dermatol Treat. 2012;23: 16-20.
39. Holme J, Tomlinson JW, Stockley RA, Stewart PM, Barlow N, Sullivan AL. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J. 2008;32: 1047-1052.
40. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63: 200-207.
41. Einaudi S, Bertorello N, Masera N, et al. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50: 537-541.
42. Kuperman H, Odone Filho V, Cristofani LM, Assis de Almeida MT, Setian N, Damiani D. Evaluation of adrenal reserve in children with acute lymphocytic leukemia treated with prednisone or dexamethasone. Horm Res Paediatr. 2012;78: 73-80.
43. Grossmann C, Scholz T, Rochel M, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151: 397-406.
44. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9: 389-396.
45. Han HS, Shim YK, Kim JE, et al. A pilot study of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients. Support Care Cancer. 2012;20: 1565-1572.
46. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. AmJ Med. 1993;95: 258-264.
47. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992;326: 226-230.
48. Elston MS, Conaglen HM, Hughes C, Tamatea JA, Meyer-Rochow GY, Conaglen JV. Duration of cortisol suppression following a single dose of dexamethasone in healthy volunteers: a randomised double-blind placebo-controlled trial. Anaesth Intensive Care. 2013;41: 596-601.
49. Zora JA, Zimmerman D, Carey TL, O'Connell EJ, Yunginger JW. Hypothalamic-pituitary-adrenal axis suppression after short-term, high-dose glucocorticoid therapy in children with asthma. J Allergy Clin Immunol. 1986;77: 9-13.
50. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43: 343-373.
51. Sacre K, Dehoux M, Chauveheid MP, et al. Pituitary-adrenal function after prolonged glucocorticoid therapy for systemic inflammatory disorders: an observational study. J Clin Endocrinol Metab. 2013;98: 3199-3205.
52. Huber BM, Bolt IB, Sauvain MJ, Fluck CE. Adrenal insufficiency after glucocorticoid withdrawal in children with rheumatic diseases. Acta Paediatr. 2010;99: 1889-1893.
53. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355: 542-545.
54. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348: 727-734.
55. Xu J, Sabarinath SN, Derendorf H. Cortisol suppression as a surrogate marker for inhaled corticosteroid-induced growth retardation in children. Eur J Pharm Sci. 2009;36: 110-121.
56. Priestley JT, Sprague RG, Walters W, Salassa RM. Subtotal adrenalectomy for Cushing's syndrome: a preliminary report of 29 cases. Ann Surg. 1951;134: 464-475.
57. Doherty GM, Nieman LK, Cutler GB Jr, Chrousos GP, Norton JA. Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing's syndrome. Surgery. 1990;108: 1085-1090.
58. Alexandraki KI, Kaltsas GA, Isidori AM, et al. Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol. 2013;168: 639-648.
59. Hassan-Smith ZK, Sherlock M, Reulen RC, et al. Outcome of Cushing's disease following transsphenoidal surgery inasingle center over 20 years. J Clin Endocrinol Metab. 2012;97: 1194-1201.
60. Lodish M, Dunn SV, Sinaii N, Keil MF, Stratakis CA. Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing's disease. J Clin Endocrinol Metab. 2012;97: 1483-1491.
61. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin- dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93: 2454-2462.
62. Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP. The pituitary corticotroph is not the rate limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing syndrome. J Clin Endocrinol Metab. 1993;77: 173-177.
63. Avgerinos PC, Nieman LK, Oldfield EH, et al. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease. J Clin Endocrinol Metab. 1989;68: 912-916.
64. Roelfsema F, Keenan DM, Veldhuis JD. Endogenous ACTH concentration- cortisol secretion dose analysis unmasks decreased ACTH potency in Cushing's disease with restoration after successful pituitary adenomectomy. J Clin Endocrinol Metab. 2011;96: 3768-3774.
65. Walz MK, Alesina PF, Wenger FA, et al. Posterior retroperitoneoscopic adrenalectomy-results of 560 procedures in 520 patients. Surgery. 2006;140: 943-948; discussion 948-950.
66. Klose M, Jorgensen K, Kristensen LO. Characteristics of recovery of adrenocortical function after treatment for Cushing's syndrome due to pituitary or adrenal adenomas. Clin Endocrinol (Oxf). 2004;61: 394-399.
67. Pimentel-Filho FR, Cukiert A, Miyashita F, et al. Adrenocorticotropin levels do not change during early recovery of transsphenoidal surgery for ACTH-secreting pituitary tumors. J Endocrinol Invest. 2001;24: 83-87.
68. Toms GC, McCarthy MI, Niven MJ, Orteu CH, King TT, Monson JP. Predicting relapse after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 1993;76: 291-294.
69. Porterfield JR, Thompson GB, Young WF Jr, et al. Surgery for Cushing's syndrome: an historical review and recent ten-year experience. World J Surg. 2008;32: 659-677.
70. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31: 301-342.
71. Agha A, Rogers B, Sherlock M, O'Kelly P, Tormey W, Phillips J, Thompson CJ. Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab. 2004;89: 4929-4936.
72. Nieman LK. Dynamic evaluation of adrenal hypofunction. J Endocrinol Invest. 2003;26: 74-82.
73. McLaughlin N, Cohan P, Barnett P, Eisenberg A, Chaloner C, Kelly DF. Early morning cortisol levels as predictors of short-term and long-term adrenal function after endonasal transsphenoidal surgery for pituitary adenomas and Rathke's cleft cysts. World Neurosurg. 2013;80: 569-575.
74. Reynolds RM, Stewart PM, Seckl JR, Padfield PL. Assessing the HPA axis in patients with pituitary disease: a UK survey. Clin Endocrinol (Oxf). 2006;64: 82-85.
75. Agha A, Tomlinson JW, Clark PM, Holder G, Stewart PM. The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitaryadrenal axis. J Clin Endocrinol Metab. 2006;91: 43-47.
76. Gleeson HK, Walker BR, Seckl JR, Padfield PL. Ten years on: safety of short synacthen tests in assessing adrenocorticotropin deficiency in clinical practice. J Clin Endocrinol Metab. 2003;88: 2106-2111.
77. Maghnie M, Uga E, Temporini F, et al. Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic- pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol. 2005;152: 735-741.
78. Petersenn S, Quabbe HJ, Schofl C, Stalla GK, von Werder K, Buchfelder M. The rational use of pituitary stimulation tests. Dtsch Arztebl Int. 2010;107: 437-443.
79. Gonzalbez J, Villabona C, Ramon J, et al. Establishment of reference values for standard dose short synacthen test (250 micrograms), low dose short synacthen test (1 microgram) and insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in normal subjects. Clin Endocrinol (Oxf). 2000;53: 199-204.
80. Ionita IA, Fast DM, Akhlaghi F. Development of a sensitive and selective method for the quantitative analysis of cortisol, cortisone, prednisolone and prednisone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877: 765-772.
81. Suliman AM, Smith TP, Labib M, Fiad TM, McKenna TJ. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf). 2002;56: 533-539.
82. Plumpton FS, Besser GM. The adrenocortical response to surgery and insulin-induced hypoglycaemia in corticosteroid-treated and normal subjects. Br J Surg. 1969;56: 216-219.
83. Chitale A, Musonda P, McGregor AM, Dhatariya KK. Determining the utility of the 60 min cortisol measurement in the short synacthen test. Clin Endocrinol (Oxf). 2013;79: 14-19.
84. Jones SL, Trainer PJ, Perry L, Wass JA, Bessser GM, Grossman A. An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year. Clin Endocrinol (Oxf). 1994;41: 123-128.
85. Avgerinos PC, Chrousos GP, Nieman LK, Oldfield EH, Loriaux DL, Cutler GB Jr. The corticotropin-releasing hormone test in the postoperative evaluation of patients with Cushing's syndrome. J Clin Endocrinol Metab. 1987;65: 906-913.
86. Rao RH, Spathis GS. Intramuscular glucagon as a provocative stimulus for the assessment of pituitary function: growth hormone and cortisol responses. Metabolism. 1987;36: 658-663.
87. FiadT M, Kirby JM, Cunningham SK, McKenna TJ. The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf). 1994;40: 603-609.
88. Agha A, Monson JP. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin Endocrinol (Oxf). 2007;66: 459-465.
89. Qureshi AC, Bahri A, Breen LA, et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf). 2007;66: 632-635.
90. Bhattacharyya A, Kaushal K, Tymms DJ, Davis JR. Steroid withdrawal syndrome after successful treatment of Cushing's syndrome: a reminder. Eur J Endocrinol. 2005;153: 207-210.
91. Kazama I, Komatsu Y, Ohiwa T, Sanayama K, Nagata M. Delayed adrenal insufficiency long after unilateral adrenalectomy: prolonged glucocorticoid therapy reduced reserved secretory capacity of cortisol. Int J Urol. 2005;12: 574-577.
92. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. 2011;96: 2004-2015.
93. He HC, Dai J, Shen ZJ, et al. Retroperitoneal adrenal-sparing surgery for the treatment of Cushing's syndrome caused by adrenocortical adenoma: 8-year experience with 87 patients. World J Surg. 36: 1182-1188.
94. Ragnarsson O, Nystrom HF, Johannsson G. Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism. Clin Endocrinol (Oxf). 2012;76: 246-252.
95. Benson S, Neumann P, Unger N, et al. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. Eur J Endocrinol. 2012;167: 679-685.
96. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr Disord. 2012;12: 8.
97. Agha A, Liew A, Finucane F, et al. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency. Clin Endocrinol (Oxf). 2004;60: 688-693.
98. Peters CJ, Hill N, Dattani MT, Charmandari E, Matthews DR, Hindmarsh PC. Deconvolution analysis of 24-h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 2013;78: 347-351.
99. Behan LA, Rogers B, Hannon MJ, et al. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. Clin Endocrinol (Oxf). 2011;75: 505-513.
100. Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012;97: 473-481.
101. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002; 87: 2046-2052.
102. McHenry CM, Bell PM, Hunter SJ, et al. Effects of dehydroepiandrosterone sulphate (DHEAS) replacement on insulin action and quality of life in hypopituitary females: a double-blind, placebocontrolled study. Clin Endocrinol (Oxf). 2012;77: 423-429.
103. Akahori H. Reversible impairment of the processing of proopiomelanocortin into ACTH in pituitary enlargement suspected of lymphocytic hypophysitis. Endocr J. 2012;59: 1121-1129.
104. O'Sullivan EP, Woods C, Glynn N, et al. The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 2009;71: 709-714.
105. Liu ZH, Chang CN, Pai PC, et al. Clinical features and surgical outcome of clinical and subclinical pituitary apoplexy. J Clin Neurosci. 2010;17: 694-699.
106. Hannon MJ, Behan LA, O'Brien MM, et al. Hyponatremia following mild/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting. J Clin Endocrinol Metab. 2014;99: 291-298.
107. Abdelmannan D, Chaiban J, SelmanWR, Arafah BM. Recurrences of ACTH-secreting adenomas after pituitary adenomectomy can be accurately predicted by perioperative measurements of plasma ACTH levels. J Clin Endocrinol Metab. 2013;98: 1458-1465.
108. Acebes JJ, Martino J, Masuet C, Montanya E, Soler J. Early postoperative ACTH and cortisol as predictors of remission in Cushing's disease. Acta Neurochir (Wien). 2007;149: 471-477; discussion 477-479.
109. Burke CW, Adams CB, Esiri MM, Morris C, Bevan JS. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome? Clin Endocrinol (Oxf). 1990; 33: 525-537.
110. Costenaro F, Rodrigues TC, Rollin GA, N PF, Czepielewski MA. Evaluation of Cushing's disease remission after transsphenoidal surgery based on early serum cortisol dynamics. Clin Endocrinol (Oxf). 2014;80: 411-418.
111. Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J. 2003;50: 399-408.
112. Estrada J, Garcia-Uria J, Lamas C, et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2001;86: 5695-5699.
113. Lamberts SW, Klijn GM, de Jong JG, Birkenhager JC. The recovery of the hypothalamo-pituitary-adrenal axis after transsphenoidal operation in three patients with Cushing's disease. The effect of prior external pituitary irradiation. Acta Endocrinol (Copenh). 1981;98: 580-585.
114. Mishra AK, Agarwal A, Gupta S, Agarwal G, Verma AK, Mishra SK. Outcome of adrenalectomy for Cushing's syndrome: experience from a tertiary care center. World J Surg. 2007;31: 1425-1432.
115. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56: 541-551.
116. Yamaji T, Ishibashi M, Sekihara H, Itabashi A, Yanaihara T. Serum dehydroepiandrosterone sulfate in Cushing's syndrome. J Clin Endocrinol Metab. 1984;59: 1164-1168.